XM n’offre pas ses services aux résidents des États-Unis d’Amérique.
F
F

Fresenius


Actualités

Fresenius SE: Announces EMA Acceptance For Review Of Denosumab Biosimilar Candidates

BRIEF-Fresenius SE: Announces EMA Acceptance For Review Of Denosumab Biosimilar Candidates July 11 (Reuters) - Fresenius SE & Co KGaA FREG.DE : ANNOUNCES EMA ACCEPTANCE FOR REVIEW OF DENOSUMAB BIOSIMILAR CANDIDATES Further company coverage: FREG.DE Reporting by Berlin Newsroom
F

Banco Bpm, Firstgroup, Xps Pensions

EUROPE RESEARCH ROUNDUP-Banco Bpm, Firstgroup, Xps Pensions June 11 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Banco Bpm, Firstgroup and Xps Pensions Group, on Tuesday. HIGHLIGHTS * Banco Bpm BAMI.MI : Morgan Stanley cuts to equal weight from overweight * Firstgroup Plc FGP.L : RBC raises target price to 200p from 195p * JCDecaux SE JCDX.PA : Deutsche Bank cuts to hold from buy * Next Plc NXT.L : HSBC raises target price to 9,
B
B
C
C
D
E
E
E
E
F
H
H
H
I
K
M
N
N
S
S
U
U
H
A
B
I

Ashtead Technology Holdings, Computacenter, Maersk

EUROPE RESEARCH ROUNDUP-Ashtead Technology Holdings, Computacenter, Maersk June 6 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Ashtead Technology Holdings, Computacenter and Maersk on Thursday. HIGHLIGHTS * Ashtead Technology Holdings Plc ATAS.L : Stifel raises target price to 900p from 770p * Computacenter Plc CCC.L : Morgan Stanley cuts target price to 2550p from 2650p * IG Group Holdings Plc IGG.L : Deutsche Bank cuts target
B
E
F
G
I
I
I
K
R
R
S
V
W
A
A
B
M

Fresenius lifts 2024 targets for private healthcare unit Helios

Fresenius lifts 2024 targets for private healthcare unit Helios June 5 (Reuters) - German healthcare group Fresenius FREG.DE raised the yearly guidance for its private healthcare provider Helios on Wednesday, following a strong start to 2024 and the conclusion of group-wide restructuring. The Hessian-based group expects Helios to grow its revenue by a mid-single-digit percentage and report an earnings before interests and taxes (EBIT) margin of 10% to 11% this year.
F
F

Top of the Street: Fresenius, Freenet, European tyremakers

BUZZ-Top of the Street: Fresenius, Freenet, European tyremakers A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** UBS upgrades mobile retailer and service provider Freenet FNTGn.DE to "buy" from "hold", saying it benefits from competitive tensions in the German mobile market that have pushed operators to give it longer term deals ** HSBC raises German healthcare group Fresenius FREG.DE to "buy" from "hold" and increases its TP by 23% to 38 euros INITIATION
C
F
F
H
F

Allianz, Carnival, Future

EUROPE RESEARCH ROUNDUP-Allianz, Carnival, Future June 4 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Allianz, Carnival and Future, on Tuesday. HIGHLIGHTS * Allianz SE ALVG.DE : Citigroup cuts to neutral from buy * Carnival CCL.L : Peel Hunt raises to buy from add * Future Plc FUTR.L : Berenberg raises to buy from hold * Liontrust Asset Management Plc LIO.L : Deutsche Bank cuts to sell from hold * Nibe NIBEB.ST : Barclays cuts t
A
A
C
D
F
F
H
I
I
K
L
L
M
N
P
R
A
A
A
B
F
P
Z

Fresenius - Sang-Jin Pak Takes Over Management Of Biopharma At Fresenius Kabi

BRIEF-Fresenius - Sang-Jin Pak Takes Over Management Of Biopharma At Fresenius Kabi May 29 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : DR. SANG-JIN PAK TAKES OVER THE MANAGEMENT OF THE BIOPHARMA BUSINESS AT FRESENIUS KABI WITH EFFECT FROM JUNE 1, 2024 MICHAEL SCHÖNHOFEN, HEAD OF BIOPHARMA AND MEMBER OF THE FRESENIUS KABI MANAGEMENT BOARD, LEAVES
F

Fresenius Says FDA Accepts For Review Denosumab Biosimilar Application

BRIEF-Fresenius Says FDA Accepts For Review Denosumab Biosimilar Application May 27 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : ANNOUNCES FDA ACCEPTANCE FOR REVIEW OF DENOSUMAB BIOSIMILAR APPLICATION Further company coverage: FREG.DE (Gdansk Newsroom)
F

FLSmidth, Neste, Sonova Holding

EUROPE RESEARCH ROUNDUP- FLSmidth, Neste, Sonova Holding May 20 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including FLSmidth, Neste and Sonova Holding, on Monday. HIGHLIGHTS * FLSmidth FLS.CO : JP Morgan raises target price to DKK 400 from DKK 310 * IMCD NV IMCD.AS : JP Morgan cuts target price to EUR 185 from EUR 188 * Neste Oyj NESTE.HE : Stifel cuts target price to EUR 37 from EUR 40 * Sonova Holding AG SOON.S : Morgan Stanley cuts
B
C
C
E
E
E
F
F
G
N
P
R
S
S
S
S
T
U
U
V
A
F
R

Investors demand clarity from Fresenius over dialysis group FMC

Investors demand clarity from Fresenius over dialysis group FMC FRANKFURT, May 17 (Reuters) - Investors demanded more clarity from German healthcare group Fresenius SE FREG.DE on Friday regarding its plans to cede strategic control over dialysis group Fresenius Medical Care FMEG.DE . "The volatility at Fresenius Medical Care seems to repeatedly overshadow the recent positive operating developments at Fresenius and is also deterring many potential shareholders from investing in Fresenius," said H
F
F

Alfa Laval, OMV AG, Unilever Plc

EUROPE RESEARCH ROUNDUP- Alfa Laval, OMV AG, Unilever Plc May 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Alfa Laval, OMV AG and Unilever Plc, on Tuesday. HIGHLIGHTS * Alfa Laval ALFA.ST : JP Morgan raises target price to SEK 385 from SEK 325 * Babcock International BAB.L : Citigroup raises target price to 640p from 530p * OMV AG OMVV.VI : Morgan Stanley raises to equal weight from underweight * SKAN Group AG SKAN.S : Baader
A
A
A
B
C
C
D
F
G
H
I
I
I
L
M
O
O
P
S
S
S
T
A
B
B
D
J
P

Coloplast, National Grid, Smurfit Kappa

EUROPE RESEARCH ROUNDUP- Coloplast, National Grid, Smurfit Kappa May 13 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Coloplast, National Grid and Smurfit Kappa, on Monday. HIGHLIGHTS * AFC Ajax NV AJAX.AS : Berenberg cuts to hold from buy; cuts PT to EUR 11 from EUR 17 * Coloplast COLOB.CO : HSBC raises target price to DKK 710 from DKK 700 * JD Wetherspoon JDW.L : HSBC raises target price to 1030p from 1020p * National Grid NG.L
A
E
F
M
M
R
U
A
B
B
B
B
E
F
I
J
N
S

Fresenius Q1 Group EBITDA Before Special Items Up 13% At EUR 924 Mln

BRIEF-Fresenius Q1 Group EBITDA Before Special Items Up 13% At EUR 924 Mln May 8 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : Q1 GROUP REVENUE UP 4% AT EUR 5.7 BILLION Q1 GROUP EBITDA BEFORE SPECIAL ITEMS UP 13% AT EUR 924 MILLION Q1 GROUP NET INCOME BEFORE SPECIAL ITEMS UP 10% AT EUR 429 MILLION Q1 GROUP EBIT BEFORE SPECIAL ITEMS UP 15% AT EUR 633
F

Fresenius Q1 beat, outlook hike boosts shares

BUZZ-Fresenius Q1 beat, outlook hike boosts shares ** Fresenius's FREG.DE stock rises around 3% in early Frankfurt trade after the German healthcare group raised its full-year outlook and reported better-than-expected Q1 results ** It now expects its organic group revenue to grow by 4%-7% this year, up from a previously expected 3%-6% ** First-quar
F
G

Fresenius marks restructuring end with Vamed exit, raises outlook

UPDATE 3-Fresenius marks restructuring end with Vamed exit, raises outlook Adds detail on Vamed exit in paragraphs 1-3, CEO quote in paragraph 4, analyst comment in paragraph 6 By Tristan Veyet May 8 (Reuters) - Germany's Fresenius FREG.DE said on Wednesday it had completed its restructuring with a "structured exit" from its loss-making service unit Vamed as it raised its outlook for 2024 after beating first-quarter forecasts.
F
F

Fresenius SE: Fresenius Exits Its Investment Company Vamed

BRIEF-Fresenius SE: Fresenius Exits Its Investment Company Vamed May 8 (Reuters) - Fresenius Se FREG.DE : FRESENIUS EXITS ITS INVESTMENT COMPANY VAMED VAMED’S OPERATIONS IN AUSTRIA TO BE SOLD TO AN AUSTRIAN CONSORTIUM OF CONSTRUCTION COMPANIES, PORR AND STRABAG VAMED’S HOSPITAL SERVICES UNIT TO BE TRANSFERRED TO THE FRESENIUS GROUP VAMED'S INTE
F

German healthcare group Fresenius Q1 EBIT beats expectations

German healthcare group Fresenius Q1 EBIT beats expectations May 7 (Reuters) - German healthcare group Fresenius FREG.DE first quarter results beat expectations, the company said on Wednesday, citing strong performance at its operating companies. First-quarter earnings before interests and taxes (EBIT) were 633 million euros ($679.78 million). That was above investors' expectation of 606 million euros, according to a consensus of forecasts from Vara research.
F
F

Fresenius Raises Outlook For Fiscal Year 2024

BRIEF-Fresenius Raises Outlook For Fiscal Year 2024 May 7 (Reuters) - Fresenius SE & Co KGaA FREG.DE : EQS-ADHOC: FRESENIUS SE & CO. KGAA: FRESENIUS RAISES OUTLOOK FOR FISCAL YEAR 2024 FRESENIUS NOW EXPECTS ORGANIC GROUP REVENUE GROWTH BETWEEN 4 AND 7% FOR FISCAL YEAR 2024 (PREVIOUSLY: 3 TO 6%) FY EBIT MARGIN IS NOW EXPECTED TO RANGE BETWEEN 15 AND
F

Germany corporate earnings week ahead

DIARY-Germany corporate earnings week ahead May 3 (Reuters) - Diary of Germany (.GDAXI) corporate earnings for the week ahead GERMANY EARNINGS Start Date Start Time(GMT) RIC Company Name Event Name 07-May-2024 NTS IFXGn.DE Infineon Technologies AG Q2 2024 Infineon Technologies AG Earnings Release 07-May-2024 NTS SHLG.DE Siemens Healthineers AG Q2 2024 Siemens Healthineers AG Earnings Release 07-May-2024 05:00 DHLn.DE Deutsche Post AG Q1 2024 Deutsche Post AG Earnings Release 07-May-2024 05:00 ZA
B
C
F
H
I
S
Z
G

Fresenius To Divest Vamed's Rehabilitation Business

BRIEF-Fresenius To Divest Vamed's Rehabilitation Business May 2 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE : DIVESTS VAMED'S REHABILITATION BUSINESS PAI PARTNERS ("PAI") TO ACQUIRE CONTROLLING MAJORITY OF 67 PERCENT, FRESENIUS TO RETAIN 33 PERCENT TO PARTICIPATE IN FUTURE UPSIDES CLOSING EXPECTED IN SECOND HALF OF YEAR Further company coverage: FRE
F



Conditions

Actifs populaires

Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.

Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.

Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.

Avertissement sur les risques : votre capital est à risque. Les produits à effet de levier ne sont pas recommandés pour tous. Veuillez consulter notre Divulgation des risques